Search results
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non...
WTNH-TV New Haven· 1 day ago"The high complete response rate and durability of these responses observed in patients treated with...
CG sets new bar in bladder cancer, validating rare biotech IPO success story
FierceBiotech· 1 day agoCG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling ...
...LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in...
Fort Wayne Journal Gazette· 2 days ago(Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive < ...
ImmunityBio partners with Serum Institute for cancer treatment supply By Investing.com
Investing.com· 2 days agoThe partnership aims to address the global shortage of BCG supplies by producing both standard BCG...
...Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer...
Benzinga· 8 hours agoUroGen Pharma Ltd. URGN, a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results ...
CG follows big IPO with new results for bladder cancer drug
BioPharma Dive via Yahoo Finance· 2 days agoNewly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year,...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 2 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Olympus to Highlight Diverse Treatment Portfolio at American Urological Association Annual Meeting
FOX21 Colorado Springs· 4 days ago... single-use flexible ureteroscope system, the company's first single-use ureteroscope, and the ESG-410™ Surgical Energy Platform which supports procedural approaches and efficiencies in the treatment of NMIBC (non-muscle-invasive bladder cancer), benign prostatic hyperplasia (BPH), as well as a...
Biodexa gains license for polyposis asset as stock more than doubles
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe study which is supported with $3m in funding from the National...
ImmunityBio shares target raised on Anktiva pricing strategy By Investing.com
Investing.com· 5 days agoThe adjustment follows the recent approval of ImmunityBio's Anktiva for the treatment of...